Institute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College St. Rosebrugh Building, Toronto, ON, Canada, M5S 3G9.
J Cardiovasc Transl Res. 2011 Oct;4(5):592-602. doi: 10.1007/s12265-011-9307-x. Epub 2011 Jul 12.
Cardiovascular diseases are the leading cause of death worldwide, and cell-based therapies represent a potential cure for patients with cardiac diseases such as myocardial infarction, heart failure, and congenital heart diseases. Towards this goal, cardiac tissue engineering is now being investigated as an approach to support cell-based therapies and enhance their efficacy. This review focuses on the latest research in cardiac tissue engineering based on the use of embryonic, induced pluripotent, or adult stem cells. We describe different strategies such as direct injection of cells and/or biomaterials as well as direct replacement therapies with tissue mimics. In this regard, the latest research has shown promising results demonstrating the improvement of cardiac function with different strategies. It is clear from recent studies that the most important consideration to be addressed by new therapeutic strategies is long-term functional improvement. For this goal to be realized, novel and efficient methods of cell delivery are required that enable high cell retention, followed by electrical integration and mechanical coupling of the injected cells or the engineered tissue to the host myocardium.
心血管疾病是全球范围内的主要死因,细胞疗法为心肌梗死、心力衰竭和先天性心脏病等心脏疾病患者提供了潜在的治疗方法。为此,心脏组织工程学正被作为一种支持细胞疗法和提高其疗效的方法进行研究。本综述重点介绍了基于胚胎、诱导多能或成体干细胞的心脏组织工程学的最新研究。我们描述了不同的策略,如细胞和/或生物材料的直接注射以及组织模拟的直接替代疗法。在这方面,最近的研究表明,不同策略在改善心脏功能方面取得了有前景的结果。从最近的研究中可以清楚地看出,新的治疗策略需要解决的最重要考虑因素是长期功能改善。为了实现这一目标,需要新的、有效的细胞输送方法,这些方法能够实现高细胞保留率,然后使注入的细胞或工程组织与宿主心肌进行电整合和机械偶联。